U.S. Markets open in 5 hrs 47 mins
  • S&P Futures

    3,796.00
    +2.00 (+0.05%)
     
  • Dow Futures

    30,311.00
    +1.00 (+0.00%)
     
  • Nasdaq Futures

    11,641.00
    +17.25 (+0.15%)
     
  • Russell 2000 Futures

    1,769.10
    +1.10 (+0.06%)
     
  • Crude Oil

    87.87
    +0.11 (+0.13%)
     
  • Gold

    1,731.60
    +10.80 (+0.63%)
     
  • Silver

    20.72
    +0.18 (+0.86%)
     
  • EUR/USD

    0.9920
    -0.0066 (-0.6646%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    28.72
    -0.35 (-1.20%)
     
  • GBP/USD

    1.1359
    -0.0115 (-1.0064%)
     
  • USD/JPY

    144.5780
    +0.3790 (+0.2628%)
     
  • BTC-USD

    20,207.68
    -54.62 (-0.27%)
     
  • CMC Crypto 200

    459.21
    +0.80 (+0.17%)
     
  • FTSE 100

    7,065.04
    +12.42 (+0.18%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

·4 min read

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So, the natural question for NeuroSense Therapeutics (NASDAQ:NRSN) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.

Check out our latest analysis for NeuroSense Therapeutics

How Long Is NeuroSense Therapeutics' Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2022, NeuroSense Therapeutics had cash of US$14m and no debt. Looking at the last year, the company burnt through US$1.6m. Therefore, from March 2022 it had 8.8 years of cash runway. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is NeuroSense Therapeutics' Cash Burn Changing Over Time?

NeuroSense Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. In fact, it ramped its spending strongly over the last year, increasing cash burn by 114%. That sort of ramp in expenditure is no doubt intended to generate worthwhile long term returns. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Easily Can NeuroSense Therapeutics Raise Cash?

Given its cash burn trajectory, NeuroSense Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

NeuroSense Therapeutics' cash burn of US$1.6m is about 6.7% of its US$23m market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

How Risky Is NeuroSense Therapeutics' Cash Burn Situation?

As you can probably tell by now, we're not too worried about NeuroSense Therapeutics' cash burn. For example, we think its cash runway suggests that the company is on a good path. Although we do find its increasing cash burn to be a bit of a negative, once we consider the other metrics mentioned in this article together, the overall picture is one we are comfortable with. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Taking a deeper dive, we've spotted 5 warning signs for NeuroSense Therapeutics you should be aware of, and 3 of them can't be ignored.

Of course NeuroSense Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here